Molecular imaging with positron emission tomography (PET) using zirconium-89 (89 Zr) ... This causes an "antigen sink" that absorbs the tracer dose, leaving insufficient 89 Zr-mAb to target all tumor lesions. Therefore, for each mAb, information should be obtained to assess whether a dose-dependent correlation between imaging …

Immuno-PET detection of LAG-3 expressing intratumoral lymphocytes using the zirconium-89 radiolabeled fully human anti-LAG-3 antibody REGN3767 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 …

The prior primate SIV immunoPET study demonstrated increased tracer uptake in nasopharyngeal associated lymphoid tissue (NALT) 6, and we also observed …

Molecular imaging is based on two important concepts of the "Tracer Principle" and the "Magic Bullet", which were developed respectively by George de Hevey and Paul Ehrlich. ... (64 Cu) and zirconium-89 (89 Zr) . Zirconium-89 (89 Zr) Early studies about 89 Zr and its radiochemistry were reported (in the 1960 s) by the National …

Objective: To investigate the imaging and biodistribution of a novel zirconium-89 (89 Zr)-labeled mouse anti-cd20 monoclonal antibody (mAb) in control and experimental autoimmune encephalomyelitis (EAE) mice following subcutaneous (s. c.) and intravenous (i.v.) administration. Background: Anti-cd20-mediated B-cell depletion using …

Keywords LAG-3 · PD-1 · PET · Zirconium-89 · Immunotherapy · TILs This article is part of the Topical Collection on Oncology - General. ... (C1D8), the zirconium-89-labelled LAG-3 tracer ([89 Zr]Zr-BI 754111) was administered, which contained 37 MBq of [89 Zr] Zr-BI 754111 and 4 mg of BI 754111. Whole-body PET/CT

Previously, we developed a zirconium-89 PET tracer based on a long-circulating glucagon-like peptide 1 receptor agonist (GLP-1RA) using desferrioxamine (DFO) as a chelator. Here, we aimed to develop an improved zirconium-89-labeled GLP-1RA with increased molar activity to increase the uptake in low receptor density tissues, such as …

A direct comparison between 89 Zr-bevacizumab and an irrelevant 89 Zr-labeled IgG revealed a significantly higher tumor uptake of 89 Zr-bevacizumab in nude mice with human ovarian SK-OV-3 tumors . Besides using 89 Zr-bevacizumab as PET tracer for noninvasive in vivo imaging of VEGF expression in the tumor microenvironment, potentially it can ...

89 Zr is an emerging radionuclide that plays an essential role in immuno-positron emission tomography (PET) imaging. The long half-life of 89 Zr (t 1/2 = 3.3 days) is favorable for evaluating the in vivo distribution of monoclonal antibodies. Thus, the use of 89 Zr is promising for monitoring antibody-based cancer therapies. Immuno-PET combines …

A direct comparison between 89 Zr-bevacizumab and an irrelevant 89 Zr-labeled IgG revealed a significantly higher tumor uptake of 89 Zr-bevacizumab in nude mice with human ovarian SK-OV-3 tumors . Besides using 89 Zr-bevacizumab as PET tracer for noninvasive in vivo imaging of VEGF expression in the tumor microenvironment, …

Zirconium-89 is an effective radionuclide for antibody-based positron emission tomography (PET) ... An improved chelator for 89 Zr 4+ could eliminate the release of osteophilic 89 Zr 4+ and lead to a safer PET tracer with reduced background radiation dose. Herein, we present an octadentate chelator 3,4,3-(LI-1,2-HOPO) (or …

This review article will. summarize the current status of PET tracers based on 89 Zr. Zirconium is a transition metal in Group IVB of the periodic table. 89 Zr, which decays by. positron emission ...

The positron emitter zirconium-89 (89Zr) has very attractive properties for positron emission tomography (PET) imaging of intact monoclonal antibodies (mAbs) using immuno-PET. ... Trace metal ions ...

A PET tracer, zirconium-89 nanocolloidal albumin, dedicated to lymphatic mapping and sentinel lymph node detection using high-resolution PET-CT was developed recently. Compared with gamma-based techniques, improved detection and precise localization of SLNs could be achieved on PET-CT in recently conducted clinical feasibility studies.

Immuno-PET using desferrioxamine (DFO)-conjugated zirconium-89 ([89 Zr]Zr 4+)-labeled antibodies is a powerful tool used for preclinical and clinical molecular imaging.However, a comprehensive study evaluating the variables involved in DFO-conjugation and 89 Zr-radiolabeling of antibodies, and their impact on the in vitro and in …

Here we present the initial results from a first-in-human study to assess the feasibility of imaging with zirconium-89-labeled atezolizumab (anti-PD-L1), including ... a function of tracer exposure and target expression, was high in lymphoid tissues and at sites of inflammation. In tumors, uptake was generally high but heterogeneous, varying ...

Immuno-PET using desferrioxamine (DFO)-conjugated zirconium-89 ([89Zr]Zr4+)-labeled antibodies is a powerful tool used for preclinical and clinical molecular imaging. However, a comprehensive study evaluating the variables involved in DFO-conjugation and 89Zr-radiolabeling of antibodies, and their impact on the in vitro and in …

Zirconium-89 has attracted huge interests and is used in tracing and quantification of slow biological processes and labeling of long half-live biomolecules such as monoclonal antibodies for pharmacokinetic studies and clinical trials. In this review, a concise introduction to targetry, irradiation data, separation and coordination chemistry …

Metallic radionuclides conjugated to biological vectors via an appropriate chelator are employed in nuclear medicine for the diagnosis (imaging) and radiotherapy of diseases. For the application of radiolabeled antibodies using positron emission tomography (immunoPET), zirconium-89 has gained increasing interest over the last decades as its …

Positron emission tomography (PET) imaging is used in drug development to noninvasively measure biodistribution and receptor occupancy. Ideally, PET tracers retain target binding and biodistribution properties of the investigated drug. Previously, we developed a zirconium-89 PET tracer based on a long-circulating glucagon-like peptide …

The positron emission tomography (PET) radioisotope zirconium-89 (89 Zr) is particularly suited for antibody imaging, ... 25 µg and 100 µg for each tracer. PET quantification showed [89 Zr] ...

11 C-docetaxel has been studied in lung cancer patients, and the uptake of the tracer was predictive of response measured on subsequent CT. 142 Monoclonal antibodies such as bevacizumab can also be labeled using zirconium-89, which has a half-life of 78 hours with kinetics matching those of monoclonal antibodies.

We assessed safety, imaging dose and timing, pharmacokinetics and immunogenicity of zirconium-89-labeled, CD8-specific, one-armed antibody positron emission tomography tracer …

The study will be executed in collaboration with TRACER B.V. ("TRACER"), a CRO specializing in molecular imaging techniques and fast in-human clinical trials. The project is performed under The TRACER Excellence Program (TEP). The study will be based on APAC that is coupled to zirconium-89 without altering the functionalities of …

A zirconium-89 labelled antibody, [89 Zr]Zr-DFO-ATL2, was developed for the PET imaging of PD-L2. The tracer was generated at high radiochemical yield with high …

This causes an "antigen sink" that absorbs the tracer dose, leaving insufficient 89 Zr-mAb to target all tumor lesions. Therefore, for each mAb, information should be obtained to assess whether a dose-dependent correlation between imaging dose and tumor uptake exists. ... Performance of immuno-positron emission tomography with …

Zirconium-89 half-life of ca. 3.3 days matches the pharmacokinetics of antibodies (half-life of 3–4 days), thus rendering a more suitable isotope for antibody-based immuno-PET imaging with respect to other metallic radioisotopes such as copper-64 or yttrium-86 [4].An additional reason why zirconium-89 has been deemed in the past …

Objectives: The aim of this study was to design a novel tracer targeting programmed cell death-ligand 2 (PD-L2) to dynamically monitor PD-L2 expression and perform preclinical screening to identify patients who may benefit from immune checkpoint inhibitor therapy (ICI) therapy. Methods: 89 Zr labelling of DFO-conjugated PD-L2 antibody (ATL2) was …

Zirconium-89 (t 1/2 = 78.4 h) with a 23% positron decay branch and a maximum positron energy of 0.9 MeV is the preferred isotope for evaluation of radiopharmaceuticals with extended pharmacokinetics including large proteins, antibodies, and nanomaterials. Given its increasing commercial availability, zirconium-89 is supplanting copper-64, which ...

The PET isotope zirconium-89 (89 Zr; t 1/2 =78.4 hours) is favorable for radiolabeling mAbs, as its physical half-life matches the time mAbs require for optimal target-to-background signals.47 Recently, a first-in-human PET imaging study with 89 Zr-labeled atezolizumab (anti-PD-L1) showed that tracer uptake appeared to be a predictor of ...